Cidara Therapeutics Inc. (CDTX)
NASDAQ: CDTX
· Real-Time Price · USD
107.77
9.26 (9.40%)
At close: Oct 09, 2025, 10:56 AM
9.40% (1D)
| Bid | 107.85 |
| Market Cap | 2.73B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -91.32M |
| EPS (ttm) | -7.36 |
| PE Ratio (ttm) | -14.64 |
| Forward PE | -13.17 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 108.18 |
| Volume | 454,243 |
| Avg. Volume (20D) | 734,776 |
| Open | 102.00 |
| Previous Close | 98.51 |
| Day's Range | 102.00 - 108.48 |
| 52-Week Range | 10.14 - 108.48 |
| Beta | 1.34 |
| Ex-Dividend Date | n/a |
About CDTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CDTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CDTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 days ago
+3.54%
Cidara shares are trading higher after the company...
Unlock content with
Pro Subscription
2 weeks ago
+20.53%
Cidara Therapeutics shares are trading higher after the company announced updates to its planned Phase 3 registrational trial of CD388 following its End-of-Phase 2 meeting with the FDA.
